Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Ana Alfonso Piérola(Istituti di Ricovero e Cura a Carattere Scientifico), Naval Daver(The University of Texas MD Anderson Cancer Center), Ali N. Chamseddine(Institut Gustave Roussy), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Simona Colla(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(Wellcome Sanger Institute), Feng Wang(The University of Texas MD Anderson Cancer Center), Irene Gañán‐Gómez(The University of Texas MD Anderson Cancer Center), Graciela M. Nogueras(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jianhua Zhang(XinHua Hospital), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), G. Borthakur(The University of Texas MD Anderson Cancer Center), Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center)
Oncotarget
January 3, 2018
Cited by 65


Related Papers